AGMT Metastatic Colorectal Cancer Registry (mCRC) Third Line and Beyond
AGMT_mCRC-3L and beyond- Reg
Synopsis
Short title: AGMT_mCRC-3L and beyond- Reg
Title: AGMT Metastatic Colorectal Cancer Registry (mCRC) Third Line and Beyond
Status: open
Start: October 2024
Coordinating Investigator: Univ. Prof. Dr. Richard Greil
ClinicalTrialsID: NCT06678919
Number of patients: 500 (planned)
Sponsor: AGMT gemeinnützige GmbH
Design
This registry aims at retrospectively and prospectively evaluating the treatment landscape and clinical outcome of mCRC ≥3L in a collective attempt by including multiple oncologic centers in Austria.
The registry will be made available for all disciplines and physicians caring for cancer patients and will include patients ≥ 18 years with tissue-based diagnosis of mCRC after ≥ 2 prior lines of palliative systemic therapy including 5-FU, irinotecan, oxaliplatin, anti-VEGF, anti-EGFR (in case of RAS/BRAF wildtype), anti-PD1-therapy (in case of MSI/MMRd) in case of eligibility.
Objectives:
The goal of this registry is to build a disease-specific registry aimed at assessing the therapeutic landscape of patients with mCRC ≥3L in Austria. It will be set up to collect real-world experience in the management of patients with this disease. This registry will collect data at various sites in Austria.
Inclusion/Exclusion Criteria
Inclusion Criteria:
Physicians will select appropriate patients for enrollment. Appropriate patients are expected to:
- Age >= 18 years
- Diagnosis of mCRC
- Be willing to provide informed consent
Due to the non-interventional design of this program there are no specific in- or exclusion criteria.
Funding Support
